| Literature DB >> 32484954 |
Ioana Agache1, Cezmi A Akdis2,3, Mubeccel Akdis2, Giorgio Walter Canonica4, Thomas Casale5, Tomas Chivato6, Jonathan Corren7, Derek K Chu8, Stefano Del Giacco9, Thomas Eiwegger10,11,12, Breda Flood13, Davide Firinu9, James E Gern14, Eckard Hamelmann15, Nicola Hanania16, Irene Hernández-Martín17, Rebeca Knibb18, Mika Mäkelä19, Parameswaran Nair20,21, Liam O'Mahony22, Nikolaos G Papadopoulos23,24, Alberto Papi25, Hae-Sim Park26, Luis Pérez de Llano27, Oliver Pfaar28, Santiago Quirce29, Joaquin Sastre30, Mohamed Shamji31,32, Jurgen Schwarze33, Oscar Palomares34, Marek Jutel35,36.
Abstract
Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.Entities:
Keywords: GRADE; biologicals; cost-effectiveness; guidelines; severe asthma
Mesh：
Year: 2020 PMID： 32484954 DOI： 10.1111/all.14425
Source DB: PubMed Journal: Allergy ISSN： 0105-4538 Impact factor: 13.146